-
RBC Capital Out Positive on Neumora Therapeutics (NMRA): ' See Compelling Entry Point Ahead of Key 2H24 Catalysts'
-
Neumora Therapeutics started with Buy ratings at several Wall Street firms
-
Neumora Therapeutics (NMRA) Prices 14.71M Share IPO at $17/sh
-
Neumora Therapeutics Announces Pricing of Initial Public Offering

